{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:13:19Z","timestamp":1749701599985,"version":"3.41.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["2D43TW009343-06"],"award-info":[{"award-number":["2D43TW009343-06"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008673","name":"Center for AIDS Research, University of California, San Diego","doi-asserted-by":"publisher","award":["P30AI027763"],"award-info":[{"award-number":["P30AI027763"]}],"id":[{"id":"10.13039\/100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW009771"],"award-info":[{"award-number":["D43TW009771"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Most people living with HIV in low and middle-income countries are taking fixed dose combination tenofovir disoproxil fumarate\/lamivudine\/dolutegravir (TLD). Dolutegravir use has been associated with weight gain, a known risk factor for hypertension. We aimed to determine if weight gain in Ugandan anti-retroviral therapy (ART) na\u00efve patients on TLD correlated with increase in blood pressure.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We analyzed data from the \u2018Glucose metabolism changes in Ugandan persons with HIV (PLHIV) on Dolutegravir (GLUMED)\u2019 study which was a prospective cohort study with ART na\u00efve persons with HIV\u2009\u2265\u200918 years followed up on TLD over 48 weeks. A scatter plot with 95% confidence intervals and regression line illustrating the relationship between weight change and mean arterial pressure (MAP) change from baseline to 48 weeks was created. To further examine the effect of weight change on MAP, we performed a linear regression analysis, with MAP change as the dependent variable and weight change as the independent variable.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 220 patients\u2019 data analyzed, 129 (58.6%) were female, the median baseline age was 31 years (interquartile range (IQR): 27.0\u201338.0), the median baseline CD4 cell count was 319 cells\/mm<jats:sup>3<\/jats:sup> (IQR 160.0\u2013524.0). The median weight gain over 48 weeks was 3.0 (IQR: \u22120.1\u20136.3). We found a moderate positive linear relationship between weight gain and MAP over 48 weeks. For every increase in weight of 1\u2009kg over 48 weeks, there was an adjusted increase in MAP by 0.62mmHG.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We provide additional evidence to suggest that the noticed weight gain after starting dolutegravir based ART may be associated with a heightened risk of incident hypertension.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0325020","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:33:07Z","timestamp":1749663187000},"page":"e0325020","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir\/lamivudine\/ tenofovir disoproxil fumarate over 48 weeks"],"prefix":"10.1371","volume":"20","author":[{"given":"Willington","family":"Amutuhaire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0137-447X","authenticated-orcid":true,"given":"Nele","family":"Brusselaers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Nabwana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lal","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9708-2290","authenticated-orcid":true,"given":"Bridgette","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4831-1185","authenticated-orcid":true,"given":"Frank","family":"Mulindwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"pone.0325020.ref001","unstructured":"Global AIDS Monitoring. Indicators and questions for monitoring progress on the 2021 Political Declaration on HIV and AIDS UNAIDS 2023 GUIDANCE 2. 2021. 2024."},{"key":"pone.0325020.ref002","year":"2024"},{"key":"pone.0325020.ref003"},{"key":"pone.0325020.ref004","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"World Health Organization","year":"2018"},{"key":"pone.0325020.ref005","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.2147\/DDDT.S84850","article-title":"Dolutegravir \u2013 a review of the pharmacology, efficacy, and safety in the treatment of HIV","volume":"9","author":"CE Kandel","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"pone.0325020.ref006"},{"issue":"5","key":"pone.0325020.ref007","doi-asserted-by":"crossref","first-page":"102807","DOI":"10.1016\/j.bjid.2023.102807","article-title":"Weight gain in patients starting dolutegravir-based ART according to baseline CD4 count after 48 weeks of follow up.","volume":"27","author":"\u00c9C Cardoso-Neto","year":"2023","journal-title":"Brazilian J Infect Dis"},{"key":"pone.0325020.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101836","article-title":"Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa","volume":"57","author":"AT Brennan","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"pone.0325020.ref009","doi-asserted-by":"crossref","first-page":"2242250","DOI":"10.1080\/07853890.2023.2242250","article-title":"Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study","volume":"55","author":"AT Hirigo","year":"2023","journal-title":"Ann Med"},{"issue":"1","key":"pone.0325020.ref010","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.4102\/sajhivmed.v24i1.1500","article-title":"Weight gain on dolutegravir: Association is not the same as causation","volume":"24","author":"G Maartens","year":"2023","journal-title":"South Afr J HIV Med"},{"issue":"5","key":"pone.0325020.ref011","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/hr.2010.9","article-title":"Mechanisms of obesity-induced hypertension","volume":"33","author":"V Kotsis","year":"2010","journal-title":"Hypertension Research"},{"issue":"6","key":"pone.0325020.ref012","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"JE Hall","year":"2015","journal-title":"Circ Res"},{"issue":"1","key":"pone.0325020.ref013","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad282","article-title":"Mechanisms and treatment of obesity-related hypertension-Part 1: Mechanisms","volume":"17","author":"A Parvanova","year":"2023","journal-title":"Clin Kidney J"},{"issue":"7","key":"pone.0325020.ref014","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jiac.2021.02.003","article-title":"Changes in survival and causes of death among people living with HIV: Three decades of surveys from Tokyo, one of the Asian metropolitan cities","volume":"27","author":"H Tsuda","year":"2021","journal-title":"J Infection Chemother"},{"issue":"7","key":"pone.0325020.ref015","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3346\/jkms.2013.28.7.990","article-title":"Causes of death and risk factors for mortality among HIV-infected patients receiving antiretroviral therapy in Korea","volume":"28","author":"SH Lee","year":"2013","journal-title":"J Korean Med Sci"},{"issue":"4","key":"pone.0325020.ref016","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/hiv.12421","article-title":"Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis","volume":"18","author":"S Teeraananchai","year":"2017","journal-title":"HIV Med"},{"issue":"4","key":"pone.0325020.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059768","article-title":"Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era","volume":"8","author":"B Grinsztejn","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"pone.0325020.ref018","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25364","article-title":"HIV, antiretroviral therapy and non\u2010communicable diseases in sub\u2010Saharan Africa: empirical evidence from 44 countries over the period 2000 to 2016","volume":"22","author":"L Coetzee","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"pone.0325020.ref019","doi-asserted-by":"crossref","DOI":"10.1177\/20503121241260613","article-title":"A review of dolutegravir-associated weight gain and secondary metabolic comorbidities","volume":"12","author":"M Jemal","year":"2024","journal-title":"SAGE Open Med"},{"issue":"5","key":"pone.0325020.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00328-4","article-title":"Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts","volume":"11","author":"DM Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"issue":"1","key":"pone.0325020.ref021","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1186\/s12879-024-09655-9","article-title":"Blood glucose outcomes of anti-retroviral therapy na\u00efve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks","volume":"24","author":"F Mulindwa","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0325020.ref022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12981-023-00564-6","article-title":"Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults","volume":"20","author":"F Mulindwa","year":"2023","journal-title":"AIDS Res Ther"},{"issue":"1","key":"pone.0325020.ref023","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1186\/s12879-024-09655-9","article-title":"Blood glucose outcomes of anti-retroviral therapy na\u00efve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks","volume":"24","author":"F Mulindwa","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0325020.ref024","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12981-023-00510-6","article-title":"Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir","volume":"20","author":"F Mulindwa","year":"2023","journal-title":"AIDS Res Ther"},{"issue":"3","key":"pone.0325020.ref025","first-page":"202","article-title":"The WHO Clinical Staging System for HIV\/AIDS","volume":"12","author":"JL Weinberg","year":"2010","journal-title":"Virtual Mentor"},{"key":"pone.0325020.ref026","volume-title":"Global Physical Activity Questionnaire (GPAQ) Analysis Guide","author":"WHO","year":"2012"},{"key":"pone.0325020.ref027"},{"key":"pone.0325020.ref028"},{"key":"pone.0325020.ref029"},{"key":"pone.0325020.ref030","unstructured":"Health MOF. Ministry of Health Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda. 2020."},{"key":"pone.0325020.ref031","doi-asserted-by":"crossref","first-page":"6657003","DOI":"10.1155\/2021\/6657003","article-title":"The Prevalence and Risk Factors of Hypertension among the Urban Population in Southeast Asian Countries: A Systematic Review and Meta-Analysis","volume":"2021","author":"A Mohammed Nawi","year":"2021","journal-title":"Int J Hypertens"},{"issue":"4","key":"pone.0325020.ref032","article-title":"Risk Factors Associated With Hypertension in Young Adults: A Systematic Review","volume":"15","author":"M Meher","year":"2023","journal-title":"Cureus"},{"issue":"10","key":"pone.0325020.ref033","article-title":"Heart disease and stroke statistics-2019 update: A report from the American Heart Association","volume":"139","author":"EJ Benjamin","year":"2025","journal-title":"Circulation"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:33:13Z","timestamp":1749663193000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325020"}},"subtitle":[],"editor":[{"given":"Sarah","family":"Nanzigu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325020","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}